Evidence map›Paper›PMID 20889211›Full record

Trial reportJournal of affective disorders2011

No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C.

Ziad Kronfol, Heather J Litman, Carla Back-Madruga, Linas A Bieliauskas, Karen L Lindsay, Anna S Lok, Robert J Fontana, HALT-C Trial Group

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of affective disorders, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ziad KronfolDepression Center, Department of Psychiatry, University of Michigan, Ann Arbor, MI, United States.
Heather J Litman
Carla Back-Madruga
Linas A Bieliauskas
Karen L Lindsay
Anna S Lok
Robert J Fontana
HALT-C Trial Group
University of Michigan–Ann Arbor · USUniversity of Southern California · USNew England Research Institutes · US

Funding

ZOPOLRESTAT IN NORMOTENSIVE, TYPE 1 DIA WITH INCIPIENT NEPHROPATHYM01RR000043 · NCRR · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ZAIA, JOHN A · 1985 to 2010
$76.4M
MICHIGAN INSTITUTE FOR CLINICAL AND HEALTH RESEARCH (MICHR) (UL1): (BPCA)UL1RR024986 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SHANLEY, THOMAS P. · 2007 to 2011
$51.2M
ZINC GLUCONATE GLYCINE LOZENGES &VITAMIN C EFFECTS ON COMMON COLDM01RR000042 · NCRR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ORAL, ELIF ARIOGLU · 1985 to 2007
$40.8M
HEPATITIS C CLINICAL TRIAL-DATA COORDINATING CENTER-267092328N01DK092328 · NIDDK · NEW ENGLAND RESEARCH INSTITUTES, INC. · 1999 to 2004
$1.5M
HEPATITIS C CLINICAL TRIAL-CLINICAL CENTERSN01DK092325 · NIDDK · UNIVERSITY OF SOUTHERN CALIFORNIA · PI LINDSAY, KAREN L · 1999 to 2000
$697k
HEPATITIS C CLINICAL TRIAL-CLINICAL CENTERSN01DK092323 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOK, ANNA SF · 1999 to 2000
$233k
NCRR NIH HHS 1 UL1 RR024986NCRR NIH HHS M01 RR000042NCRR NIH HHS M01RR-00042NCRR NIH HHS M01RR-00043NIDDK NIH HHS N01-DK-9-2323NIDDK NIH HHS N01-DK-9-2325NIDDK NIH HHS N01-DK-9-2328
6 · The paper itself

Abstract

backgroundPeginterferon and ribavirin treatment of chronic hepatitis C (CHC) is frequently associated with dose-limiting neuropsychiatric toxicity. The purpose of this study is to determine whether prolonged administration of low-dose peginterferon-α2a is associated with an increase in the rate and severity of depression compared to untreated controls.

methods129 non-responders to full-dose peginterferon and ribavirin treatment were randomized to low-dose maintenance treatment with peginterferon-α2a 90 μg/week or no treatment for 3.5 years. Depression was assessed using the Beck Depression Inventory (BDI-II) and the Composite International Diagnostic Interview (CIDI) at baseline and at 12, 24, 36, and 48 months. "Clinical depression" was defined as BDI-II ≥11 and/or meeting DSM-IV criteria for major depression on the CIDI. Serial cortisol and serotonin plasma concentrations were obtained in a subgroup of patients.

resultsRates of clinical depression did not significantly differ over time or between treatment groups. Baseline clinical depression was the only significant predictor of clinical depression over time (p<0.001). Rates of clinical depression were also significantly higher in patients experiencing liver disease progression (p=0.016). Antidepressant use did not significantly differ between groups. Adjusted whole blood serotonin levels dropped significantly over time (p=0.04), but there was no group by time effect. LIMITATIONS: Lack of significant group differences in antidepressant use does not completely preclude significant mood changes masked by antidepressants. Results may differ in treatment naïve CHC patients or in those receiving full-dose peginterferon.

conclusionsProlonged low-dose peginterferon-α2a treatment is not associated with an increase in the frequency or severity of clinical depression in prior non-responder patients with chronic hepatitis C.

Indexed as

Antiviral AgentsBiomarkersDepressive DisorderDisease ProgressionFemaleHepatitis CHumansHydrocortisoneInterferon-alphaInterferon alpha-2MaleMiddle AgedPolyethylene GlycolsPsychiatric Status Rating ScalesRecombinant ProteinsSerotoninAntiviral AgentsBiomarkersHydrocortisoneInterferon-alphaInterferon alpha-2peginterferon alfa-2aPolyethylene GlycolsRecombinant ProteinsSerotonin

Identifiers

PMID20889211
PMCPMC3025085
OpenAlexW2067431237

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.